Drugs / Peptide cancer vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05059821 | Apr 2021 → Apr 2024 | hepatocellular carcinoma | zeinab ahmed yousif hasan ashour | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peptide cancer vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05059821 ↗ |
| Modality | Vaccine | “Biological: Peptide cancer vaccine” NCT05059821 ↗ |
| Route | Subcutaneous | “that administered subcutaneously monthly for six months” NCT05059821 ↗ |